相似文献
1
Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.
Blood. 2013 Jan 31;121(5):858. doi: 10.1182/blood-2012-11-465765.
2
Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone.
Eur J Haematol. 2019 Oct;103(4):385-392. doi: 10.1111/ejh.13297. Epub 2019 Aug 7.
3
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
4
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.
5
Multiple Myeloma in the Time of COVID-19.
Acta Haematol. 2020;143(5):410-416. doi: 10.1159/000507690. Epub 2020 Apr 17.
6
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Leuk Lymphoma. 2020 Jun;61(6):1323-1333. doi: 10.1080/10428194.2020.1719091. Epub 2020 Feb 22.
7
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
J Clin Oncol. 2014 Sep 1;32(25):2712-7. doi: 10.1200/JCO.2013.54.8164. Epub 2014 Jul 14.
8
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
9
Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
Leuk Lymphoma. 2010 Dec;51(12):2291-4. doi: 10.3109/10428194.2010.523128. Epub 2010 Oct 7.
10
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Blood Cancer J. 2018 Nov 8;8(11):106. doi: 10.1038/s41408-018-0147-7.
引用本文的文献
1
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma.
Arch Med Sci. 2021 Jan 11;18(3):696-703. doi: 10.5114/aoms/114269. eCollection 2022.
2
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
Neurotherapeutics. 2022 Jan;19(1):305-324. doi: 10.1007/s13311-022-01182-2. Epub 2022 Jan 24.
3
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the LRRK2 Genetic Model of Parkinson's Disease.
Front Aging Neurosci. 2020 Feb 13;12:31. doi: 10.3389/fnagi.2020.00031. eCollection 2020.
4
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
Curr Hematol Malig Rep. 2018 Apr;13(2):114-124. doi: 10.1007/s11899-018-0443-0.
5
The double-edged sword: Neurotoxicity of chemotherapy.
Blood Rev. 2015 Mar;29(2):93-100. doi: 10.1016/j.blre.2014.09.012. Epub 2014 Sep 28.
6
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases.
Clin Investig (Lond). 2013 Dec 1;3(12):1127-1138. doi: 10.4155/cli.13.108.
7
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12703-8. doi: 10.1073/pnas.1307684110. Epub 2013 Jul 15.
本文引用的文献
1
Treating myeloma: the future is already here!
Blood. 2012 Aug 30;120(9):1754-6. doi: 10.1182/blood-2012-06-434571.
2
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Blood. 2012 Aug 30;120(9):1801-9. doi: 10.1182/blood-2012-04-422683. Epub 2012 Jun 4.
3
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23.
4
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.
5
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Clin Cancer Res. 2011 May 1;17(9):2734-43. doi: 10.1158/1078-0432.CCR-10-1950. Epub 2011 Mar 1.
6
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood. 2010 Aug 5;116(5):679-86. doi: 10.1182/blood-2010-02-268862. Epub 2010 Apr 12.
7
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
J Clin Oncol. 2009 Jul 20;27(21):3518-25. doi: 10.1200/JCO.2008.18.3087. Epub 2009 Jun 15.
Zotero 插件